Ascendis Pharma

Latest Results (15.11.2025):

Ascendis Pharma reported its Q3 2025 financial results with notable revenue growth and improved operating profitability, despite recording a net loss. Total revenue reached €213.6 million—driven by successful commercial launches of YORVIPATH® and SKYTROFA®—while the company achieved an operating profit of €11.0 million. Additionally, robust cash performance and important pipeline updates, including regulatory milestones and clinical trial advancements, underpin Ascendis Pharma’s progress toward its strategic Vision 2030.

Revenue Growth & Product Performance

In Q3 2025, Ascendis Pharma reported total revenue of €213.6 million, with €143.1 million attributed to YORVIPATH® and €50.7 million to SKYTROFA®. The strong performance, including milestone revenue from global product launches, underscores the rapid market uptake of these treatments.

Operating Profit & Expense Management

Despite increased selling, general, and administrative expenses from heightened commercial expansion, Ascendis Pharma secured an operating profit of €11.0 million in Q3 2025. This reflects the company’s continued ability to leverage its growing revenue base as it manages higher operating costs.

Net Loss & Financial Position

Ascendis Pharma reported a net loss of €61.0 million in Q3 2025, influenced by significant net finance expenses, including non-cash remeasurement losses. However, the company’s cash and cash equivalents increased to €539 million, supporting its financial stability as it advances its pipeline initiatives.

Pipeline & Regulatory Milestones

The quarter also featured key pipeline developments for Ascendis Pharma. TransCon CNP is under FDA Priority Review with a PDUFA target date of November 30, 2025, while label expansion efforts continue for SKYTROFA® in adult growth hormone deficiency. These regulatory activities and clinical advancements are critical to further expanding patient access and global market presence.